In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OncoMed Pharmaceuticals, Inc.

http://www.oncomed.com

Latest From OncoMed Pharmaceuticals, Inc.

Finance Watch: October Begins With A VC Mega-Round For Newly Named Iambic

Private Company Edition: Iambic, formerly known as Entos, closed a $100m series B venture capital round to advance its AI-discovered therapeutics. Also, Evozyne raised $81m and Acesion brought in €45m in series B rounds, while Mogrify added $10m to bring its series A to $46m.

Financing Artificial Intelligence

Asia Deal Watch: HanAll, Daewoong Team With US Biotech In Parkinson's

Sino acquires Gmax's obesity drug candidate. Simcere partners with Mass General Brigham on select research projects.

Deal Watch Business Strategies

Takeda Halts Early R&D Efforts In AAV Gene Therapies And Rare Hematology

The major Japanese firm says decision prompted by desire to focus more resources on late-stage clinical candidates and core therapeutic areas, while expanding deals.

Gene Therapy Research & Development

Paul Stoffels On Galapagos’s Turnaround And Making Its Gilead Partnership Work

After scoring a long-term multi-billion dollar deal with Gilead, Galapagos rushed into clinical trials and paid the price. Paul Stoffels talks to Scrip about returning to his Belgian roots and turning around the company he co-founded.

Commercial Leadership
See All

Company Information

UsernamePublicRestriction

Register